This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Revance's (RVNC) DaxibotulinumtoxinA BLA Decision Delayed
by Zacks Equity Research
Revance (RVNC) announces a delay in the FDA decision on its BLA for DaxibotulinumtoxinA for Injection due to COVID-19.
Is a Surprise Coming for Revance (RVNC) This Earnings Season?
by Zacks Equity Research
Revance (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Revance Therapeutics (RVNC) Surges: Stock Moves 5.5% Higher
by Zacks Equity Research
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA
by Zacks Equity Research
AbbVie's (ABBV) sBLA for expanding the label of Botox for use in pediatric patients with neurogenic detrusor overactivity gets acceptance from the FDA.
Revance's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
How Revance (RVNC) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Revance (RVNC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Implied Volatility Surging for Revance Therapeutics (RVNC) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Revance Therapeutics (RVNC) stock based on the movements in the options market lately.
Will Revance Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Revance Therapeutics.
Allergan (AGN) Shareholders Approve Acquisition by AbbVie
by Kinjel Shah
Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.
Will Revance Therapeutics (RVNC) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AbbVie (ABBV) Shares Down So Far This Year: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.
Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2%
by Zacks Equity Research
Revance Therapeutics (RVNC) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Will Revance Therapeutics (RVNC) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines
by Zacks Equity Research
Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.
Revance Therapeutics (RVNC) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Revance (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Revance Therapeutics Sees Hammer Chart Pattern: Time to Buy?
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.
3 Drug/Biotech Stocks Up More Than 10% This Week
by Zacks Equity Research
The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.
Revance's Neuromodulator Injection Positive in Phase III
by Zacks Equity Research
Revance (RVNC) releases positive top-line data from two pivotal phase III trials, evaluating RT002 for reducing wrinkles between the brows. The studies meet both primary and secondary endpoints.